Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

I aim to create a $500,000 portfolio for passive income, focusing on high-yield and growth companies to outpace inflation.

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The popularity of GLP-1R drugs has catapulted the treatment landscape of obesity into the spotlight. Reformation for the ...

At the start of each of the last five years, the share price of Alkermes has increased. It’s the kind of steady trajectory ...

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge ...

We’ll hear from speakers representing Syneos Health, Flagship Pioneering, and IPSEN on pharma dealmakers’ 2025 intentions, ...

The biopharma industry’s deal-a-palooza, better known as the J.P. Morgan Healthcare Conference, has kicked off in San ...

The updated forecast for Skytrofa is exclusive of sales deductions related to prior years. In addition to the Skytrofa revenue, Ascendis Pharma provided a preliminary estimate for the total full-year ...